Clinical Trials Directory

Trials / Completed

CompletedNCT04728776

Translation and Validation of Stroke Impact Scale 3.0 in Urdu for Pakistan

Status
Completed
Phase
Study type
Observational
Enrollment
116 (actual)
Sponsor
University of Lahore · Academic / Other
Sex
Age
50 Years – 80 Years
Healthy volunteers
Not accepted

Summary

BACKGROUND Knowledge about the perceived impact of stroke on survivors' lives is still scarce in Pakistan due to the lack of translated and culturally adapted self-rating scales. The stroke impact scale is a comprehensive self-reported outcome measure designed to assess the quality of life following the stroke. Although the psychometric properties of SIS found to be superior to the conventional generic quality of life scales, it has not been translated and tested in Pakistan. OBJECTIVE To translate and cross-culturally validate the Urdu version of stroke impact scale 3.0 for Pakistan MATERIAL AND METHODS Established guidelines were followed for translation and adaption of the Stroke impact scale 3.0. A prospective cohort of 116 patients with mild to moderate stroke self-reported their recovery on the Urdu version of SIS 3.0. The patients were concurrently evaluated on the established scales to assess the validity using the Spearman correlation coefficient. ANOVA was used to determine the discriminant validity. Ninety patients were consecutively re-evaluated to determine the test-retest reliability, precision, minimal detectable change (MCD) and clinically minimally important difference. The coefficients of ICC, Cronbach's alpha, and weighted kappa were calculated to establish the stability and consistency of the scale. The receiver operating curve was used to estimate the MCID of SIS-16 using global rating scale as an anchor. KEYWORDS: Stroke, Stroke Impact Scale, Outcome Measures, Quality of Life

Conditions

Timeline

Start date
2017-02-06
Primary completion
2020-02-07
Completion
2020-02-07
First posted
2021-01-28
Last updated
2021-01-28

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT04728776. Inclusion in this directory is not an endorsement.